Press releases

Here you can find the latest news as well as what is going on at the company and within our field.



Palette Life Sciences and Nestlé Skin Health Enter into Global Licensing Agreement for Deflux®, Solesta® and Barrigel™

October 16, 2018 -

STOCKHOLM – October 15, 2018 – Palette Life Sciences AB (formerly known as Pharmanest AB*) has entered into definitive agreements with Nestlé Skin Health to license worldwide commercialization and development rights for Deflux®, Solesta® and Barrigel™. Palette is currently developing LidbreeTM for pain relief for gynecological applications. 


More about 'Palette Life Sciences and Nestlé Skin Health Enter into Global Licensing Agreement for Deflux®, Solesta® and Barrigel™'

Acerus acquires Canadian rights to novel pain relief product for gynecological procedure from Pharmanest

May 29, 2018 - Toronto, Canada, May 29 2018 – Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has entered into an exclusive agreement to commercialize Pharmanest AB (“Pharmanest”) Short Acting Lidocaine product (“SHACT”), a novel pain relief drug device combination in Canada.  
More about 'Acerus acquires Canadian rights to novel pain relief product for gynecological procedure from Pharmanest'

Helena Jansson appointed as new CEO of Pharmanest

May 18, 2018 - The Board of Pharmanest AB, a Swedish private pharmaceutical company, has appointed Helena Janson to the new CEO of the company. She is replacing Gunilla Lundmark who leaves her position after seven years. Helena Jansson comes recently from leading positions in Medivir (including the subsidiary BioPhausia) a Swedish public pharmaceutical company where she has been employed since 2000. Helena has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialisation of pharmaceutical portfolios. 
More about 'Helena Jansson appointed as new CEO of Pharmanest'

Richter signed a licensing agreement with Pharmanest to commercialize its proprietary pain relief product for gynaecological use in certain territories

October 12, 2017 - Gedeon Richter Plc. (‘Richter’) and Pharmanest AB (‘Pharmanest’) today announced that Richter will commercialise Pharmanest’s SHACT (Short Acting Lidocaine) technology, a novel innovative proprietary pain relief pharmaceutical formulation, in Europe, in Latin America and in certain other markets
More about 'Richter signed a licensing agreement with Pharmanest to commercialize its proprietary pain relief product for gynaecological use in certain territories'

Leading U.S. gynecologists see significant medical need for Pharmanest’s drug candidate SHACT

March 18, 2016 -
SOLNA, SWEDEN, MARCH 17, 2016. Every year millions of women are exposed to pain during gynecological procedures, including IUD (intrauterine device) placements. This is due to the lack of effective and user-friendly therapy for pain relief. The Swedish pharmaceutical company Pharmanest is developing a new pain relief treatment which recently received very positive reviews from leading physicians and scientists at a meeting of experts, arranged by the company in the United States. 

More about 'Leading U.S. gynecologists see significant medical need for Pharmanest’s drug candidate SHACT'

Pharmanest completes SEK 30 million rights issue and welcomes new major shareholders

July 14, 2015 - Stockholm, July 14, 2015. Pharmanest AB today announced that the company has successfully completed a rights issue of approximately SEK 30 million to new and existing owners. Östersjöstiftelsen, Recipharm Venture Fund and Praktikerinvest become new major shareholders through their participation in the rights issue and by simultaneously acquiring all shares from the former majority owner, Karolinska Development. Pharmanest also welcomes Kåre Gilstring as new shareholder. As a result of the ownership changes, Håkan Wallin has been elected new Chairman and Lars Irestedt and Carl-Johan Spak new board members.
More about 'Pharmanest completes SEK 30 million rights issue and welcomes new major shareholders'

Recipharm invests SEK 8 million in Pharmanest to support the development of Pharmanest’s lead drug candidate SHACT

July 9, 2015 - Recipharm Venture Fund AB has together with Östersjöstiftelsen and Praktikerinvest made a joint investment of SEK 28 million in Pharmanest AB. Recipharm’s part of the investment is SEK 8 million. At the same time, Karolinska Development AB and its co-investor KCIF have agreed to sell their shares in Pharmanest to the three investors in exchange for an earn out arrangement on future revenues. After completion of the transaction Recipharm will hold approximately 25 % of the shares of Pharmanest.
More about 'Recipharm invests SEK 8 million in Pharmanest to support the development of Pharmanest’s lead drug candidate SHACT'

Recipharm and Pharmanest form collaboration for commercial manufacture and supply of SHACT

July 3, 2014 - Recipharm Karlskoga AB, specialized in the manufacture of semi-solid products, and Pharmanest AB, a Stockholm-based pharmaceutical company specializing in developing products for local pain relief in obstetrics and gynecology, are pleased to announce the formation of a new pharmaceutical manufacturing contract for SHACT. 

More about 'Recipharm and Pharmanest form collaboration for commercial manufacture and supply of SHACT'

SHACT could benefit women undergoing hysteroscopies

March 25, 2014 - STOCKHOLM – March 25, 2014. Today, Pharmanest AB announced positive results from a feasibility study with its local anesthetic agent SHACT in hysteroscopy. The study demonstrated that SHACT did not interfere negatively with the examination in outpatient hysteroscopy and that it was safe and tolerable. Karolinska Development owns 63% of Pharmanest AB.
More about 'SHACT could benefit women undergoing hysteroscopies'

Pharmanest meets all efficacy and safety end points in Phase II study of SHACT

August 6, 2013 - STOCKHOLM – August 1, 2013. Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest*.
More about 'Pharmanest meets all efficacy and safety end points in Phase II study of SHACT'

Pharmanest appoints Alan Raffensperger as Chairman of the Board

November 1, 2012 - Stockholm, November 1, 2012. Today Pharmanest AB, a Karolinska Development portfolio company, announced that Alan Raffensperger, Per Langö and Gunilla Ekström have been elected as new members of the Board. Alan Raffensperger was elected Chairman. The Board of Pharmanest has hereby gained comprehensive experience in the commercialization of new, innovative products and is well prepared to progress the candidate drug SHACT, for pain relief in gynecological procedures
More about 'Pharmanest appoints Alan Raffensperger as Chairman of the Board'

Pharmanest initiates Phase II study of SHACT

June 12, 2012 -

Today, Pharmanest AB announced that the first patient has been dosed in a randomized Phase II study of SHACT, a product developed for pain relief associated with intrauterine device (IUD) insertion.


More about 'Pharmanest initiates Phase II study of SHACT'

Pharmanest initiates Phase I trial with SHACT

April 30, 2012 - Pharmanest AB today announced that the first patient has been dosed in an open label pharmacokinetic study with its drug candidate SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion. Karolinska Development AB owns 55% of Pharmanest
More about 'Pharmanest initiates Phase I trial with SHACT'

Press release from KI Science Park

February 22, 2012 - Read more at this link
Press release from KI Science Park New easier pain relief for women

Gel application will relieve pain during labor

February 20, 2012 - Giving birth should not have to be so painful, according to Swedish researchers who want to develop simpler and more effective pain relief methods to use during childbirth. This spring, in a first step, a new anesthetic will be tested in women during IUD insertion.
More about 'Gel application will relieve pain during labor'

Launch of www.pharmanest.se

May 25, 2011 - The web site was developed in collaboration with Oddville AB and we would like to thank everyone involved a job well done.

The Swedish Association of Midwives Anniversary Conference Reproductive Health May 25-27 2011.

May 25, 2011 - Welcome to our booth at the conference to learn more about what we do and our vision for pain relief. 

Gunilla Lundmark appointed New CEO of Pharmanest

August 25, 2010 - Gunilla Lundmark was appointed new chief executive officer (CEO) of Pharmanest AB. She is currently Senior Executive Vice President at Q-Med.
More about 'Gunilla Lundmark appointed New CEO of Pharmanest'